A new long-acting, once-daily basal insulin treatment has been launched in the UK for adults with type 1 and type 2 diabetes.
Insulin glargine 300units/ml (Toujeo) is a novel formulation of the existing treatment insulin glargine 100units/mL (Lantus).
“It is important that better quality insulins are developed to support the management of diabetes”
Results from trials evaluating the two showed a similar HbA1c reduction with a lower incidence of confirmed hypoglycaemia in patients with type 2 diabetes on insulin glargine 300units/mL, compared to those on 100units/ml.
In patients with type 1 diabetes, trials demonstrated similar HbA1c reduction but showed no difference in confirmed hypoglycaemia.
Insulin glargine 300units/mL also showed a more stable and more prolonged glucose lowering effect that lasted beyond 24 hours, and low within-individual blood glucose variability.
Insulin glargine 300units/mL, which is manufactured by Sanofi, was licensed by the European Medicines Agency in February.
The company noted that switching from once-daily insulin glargine 300units/mL, to insulin glargine 100 units/mL resulted in an increased risk of hypoglycaemic events, mainly in the first week after the switch.
To reduce this risk, it recommended that patients should reduce their dose by 20%.
Grace Vanterpool, a consultant diabetes nurse at Central London Community Healthcare NHS Trust and Imperial Healthcare NHS Trust, said: “Insulin is a lifesaving medication and it is important that better quality insulins are developed to support the management of diabetes.
“Toujeo is one such insulin that will give patients improved glycaemic control, reductions in hypoglycaemic events and better experience of the injection technique required,” she said.
She added: “It can also be helpful to patients with significant insulin resistance where larger doses of insulin may be required. Toujeo can be useful in reducing the volume of insulin required.”